Intersect ENT, Inc.: Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat ("ENT") medical
Source: finanznachrichten.de